Clinical Trials Logo

Epithelial Tumor clinical trials

View clinical trials related to Epithelial Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT05165433 Recruiting - Metastatic Cancer Clinical Trials

Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)

FORTIFY
Start date: April 13, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-350A in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours.

NCT ID: NCT05043714 Recruiting - Metastatic Cancer Clinical Trials

Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours

NEBULA
Start date: December 1, 2021
Phase: Phase 1
Study type: Interventional

This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-641 in combination with nivolumab (or standard of care PD-1 inhibition) in patients with metastatic or advanced epithelial tumours. The purpose is to characterize the safety and tolerability of NG-641 in combination with nivolumab in patients with metastatic or advanced epithelial tumours and to determine the recommended dose of NG-641 in combination with nivolumab for further development in patients with metastatic or advanced epithelial tumours

NCT ID: NCT04053283 Recruiting - Metastatic Cancer Clinical Trials

First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

STAR
Start date: January 23, 2020
Phase: Phase 1
Study type: Interventional

To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.

NCT ID: NCT03852511 Completed - Metastatic Cancer Clinical Trials

First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)

FORTITUDE
Start date: February 19, 2019
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability and preliminary efficacy and also pharmacokinetics, immunogenicity and other pharmacodynamic effects to elucidate the mechanism of action of NG-350A, either alone or in combination with a check point inhibitor, in patients with advanced or metastatic epithelial tumours.

NCT ID: NCT02636036 Completed - Colorectal Cancer Clinical Trials

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

SPICE
Start date: January 25, 2016
Phase: Phase 1
Study type: Interventional

This is a Phase I multicenter, open label, nonrandomized study of enadenotucirev administered in combination with nivolumab in subjects with metastatic or advanced epithelial tumors (with focus on CRC, SCCHN, escalation phase), not responding to standard therapy.